Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 1

Sponsor Class

OTHER 2INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Tumor-Agnostic 1

Conditions

Neoplasms 8Carcinoma, Non-Small-Cell Lung 6Prostatic Neoplasms 4Breast Neoplasms 4Neoplasm Metastasis 3Head and Neck Neoplasms 3Melanoma 2Glioblastoma 2Brain Neoplasms 2Advanced Solid Tumor 2Uterine Neoplasms 1Uterine Cervical Neoplasms 1Ulnar Neuropathies 1Triple Negative Breast Neoplasms 1Solid Tumor, Adult 1Prostatic Hyperplasia 1Peripheral Lung Tumor 1Pain 1Non-Muscle Invasive Bladder Neoplasms 1Non Squamous Lung Cancer 1Neuroma 1Multiple Myeloma 1Mucositis 1Lymphoma, Follicular 1Lung Neoplasms 1Leukemia, Myelogenous, Chronic, BCR-ABL Positive 1Leiomyoma 1Keratosis, Actinic 1Hyperthermia 1Glioma 1

Interventions

Carboplatin 30Cisplatin 23pembrolizumab 22Paclitaxel 21Pemetrexed 20Gemcitabine 10osimertinib 9durvalumab 9Nivolumab 9130-nm albumin-bound paclitaxel 8Sunitinib 7Sorafenib 7Fluorouracil 7Everolimus 7Docetaxel 7Axitinib 7Cetuximab 6epothilone B 51-(1-(imidazo(1,2-a)pyridin-6-yl)ethyl)-6-(1-methyl-1H-pyrazol-4-yl)-1H-(1,2,3)triazolo(4,5-b)pyrazine 5volociximab 4trebananib 4reolysin 4catumaxomab 4cabozantinib 4atezolizumab 4Radiotherapy 4Ipilimumab 4vosaroxin 3liposomal doxorubicin 3lenvatinib 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
INDUSTRY × Carcinoma × Therapeutics × Clear all
NCT02587819 2016-04-14

Investigation of the Safety and Tolerability of BSCT (Anti-nf-P2X7) 10% Ointment

Biosceptre

Phase 1 Completed
21 enrolled 9 charts
Tumor-Agnostic

Carcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡